Acknowledgements Learning objectives Privacy Policy Cookie Policy How Can We Help?

EADV 2023 HIGHLIGHTS

THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM
ELI LILLY AND COMPANY

Welcome to the

EADV 2023 Highlights!

The Highlights offer a selection of the newest and most relevant data presented at the EADV Congress 2023. Enjoy this opportunity to learn about the significant advances and breakthroughs in dermatology research and care

Today@EADV

EADV Leadership interviews

Watch the interviews with the EADV Leadership. Learn about EADV’s strategic activities and goals.

EADV Faculty interviews

Gain valuable insights from an international panel of experts.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See all

Deep Dive

Congress Summaries

Missed the presentation? Read the summaries from a selection of oral presentations and posters presented this year.

From Oral Presentations

See More
Alopecia Areata

PROs in AA: BRAVE data

Dr. Brett King

Alopecia areata impacts quality of life, and therefore patient-reported outcomes are important to assess treatment benefits. Pooled data from BRAVE-AA1 and -AA2 show that quality of life improvements correlate with regrowth of eyebrows and eyelashes, as well as on the scalp.

EADV Congress 2023 - Oral session

Patient Reported Outcomes for Scalp, Eyebrow and Eyelash hair loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 104 week Results from Two Phase 3 Clinical Trials

Read more

1-king-pros-in-aa-brave-data
Melanoma

PALGA registry data

Dr. Yannick Elshot

This nationwide cohort study from the Netherlands aims to unpick the value of sentinel lymph node biopsy as a prognostic tool in people with lentigo maligna melanoma. The findings suggest a low overall yield, but a potential role in select patient groups.

EADV Congress 2023 - Oral session

The limited value of sentinel lymph node biopsy in lentigo maligna melanoma: results of 29 years of the nationwide Dutch Pathology Registry (PALGA)

Read more

2-elshot-palga-registry-data

From Poster Presentations

See More
Atopic Dermatitis

Baricitinib in children

Prof. Dr. Andreas Wollenberg

Pediatric patients with moderate-to-severe AD treated with baricitinib continued to show improvement in signs and symptoms of AD to 52 weeks without new safety signals.

EADV Congress 2023 - Poster session

Efficacy and safety of baricitinib treatment in pediatric patients with atopic dermatitis aged 2 to less than 18 years (up to 3.6 years of exposure)

Read more

01-op-wollenberg-baricitinib-in-children
Melanoma

Imiquimod in lentigo maligna

Mrs. Marie Daude

The LM melanoma subtype is associated with subclinical extension beyond the clinical lesion margins. A new poster at EADV 2023 presents data supporting the use of neoadjuvant immunomodulation prior to excision.

EADV Congress 2023 - Poster session

Efficacy of imiquimod in the management of lentigo maligna

Read more

02-op-daude-imiquimod-in-lentigo-maligna
Feedback Newsletter

Download the app

Key Takeaways, At-a-Glance, On the Go


Or visit medfyle.com

Ask the Expert

Have a question? Submit it below.
A selection of the most interesting questions will be answered in a new video. You will receive an email when answers will be published.